The effectiveness of immune checkpoint inhibitors (cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1)) and targeted therapies (BRAF–MEK inhibitors) in melanoma patients with brain metastases have made a significant change in melanoma treatment. The gene discussed is MAP2K7; the disease is melanoma.